Matthew Grech-Sollars1,2, Katherine Ordidge1,2, Babar Vaqas3, Lesley Honeyfield2, Sameer Khan2, Sophie Camp3, David Towey2, David Peterson3, Federico Roncaroli4, Kevin S O'Neill3, Tara Barwick2,5, and Adam D Waldman1,2
1Division of Brain Sciences, Imperial College London, London, United Kingdom, 2Department of Imaging, Imperial College NHS Healthcare Trust, London, United Kingdom, 3Department of Neurosurgery, Imperial College NHS Healthcare Trust, London, United Kingdom, 4Department of Neuropathology, Imperial College NHS Healthcare Trust, London, United Kingdom, 5Department of Surgery and Cancer, Imperial College London, London, United Kingdom
Choline elevation has been reported as a marker of
aggressive glioma phenotype in numerous in
vivo MRS studies, and more recently 18F-methylcholine-PET has been applied to
glioma characterisation. This study examines the relationship between MRS and
PET choline measures in defined tumour regions, in order to validate these
against tissue biomarkers of choline metabolism and proliferation. Our initial
results raise the possibility that imaging markers of choline metabolism are influenced
by inflammatory and reactive processes for low grade tumours.
